ASCLEPIUS is funded by the European Union through the Horizon Europe Twinning programme. This initiative aims to foster institutional cooperation between public research organisations in EU Member States and Widening countries.

ASCLEPIUS aims to enhance the scientific excellence and innovation capacity of G. Eliava Institute and its esteemed twinning partners. The research component of the project aims at deepening our understanding of phage therapy – specifically against Pseudomonas aeruginosa and Staphylococcus aureus-related infectious diseases. These two bacteria are amongst the most prevalent causes of respiratory tract infections in humans.

Phage therapy, or treatment with bacteriophages, is a field, which heavily relies on the rich historical experience of Eliava Institute. Through this collaboration, the partners exchange their expertise, knowledge, and experience in areas such as bacterial biofilms research and phage bioinformatics.